News Headlines
-
TriLink BioTechnologies And Lonza Enter Into Non-Exclusive License And Supply Agreement For CleanCap mRNA Capping Technology
4/30/2024
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
-
INCOG BioPharma Services Continues Positive Momentum
4/30/2024
INCOG BioPharma Services proudly announces that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product.
-
Bespak And H&T Presspart Enter Into Collaboration Agreement To Advance Transition To Low GWP Propellants In pMDIs
4/29/2024
Bespak, a leading contract development and manufacturing organisation (CDMO) focussed on orally inhaled and nasal drug-device combination products, and H&T Presspart, a market leader in the development, manufacturing and supply of inhaled drug delivery components and devices, announced today a collaboration to accelerate the industry’s transition from existing pressurised Metered Dose Inhaler (pMDI) formulations to more climate-friendly alternatives utilising low global warming potential (GWP) propellants.
-
Lonza Launches AI-Enabled Route Scouting Service To Accelerate Small Molecule Development
4/29/2024
Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets, today announced the launch of its AI-enabled Route Scouting Service offering.
-
Miltenyi Biotec And MiLaboratories Announce Strategic Partnership To Advance Next-Generation Therapies
4/29/2024
Miltenyi Biotec, a global pioneer in biotechnology, and MiLaboratories, a leader in RNA immune technologies are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies.
-
Touchlight Awarded Grant Extension To Further Develop DNA-Enabled Biobatteries With U.S. Office For Naval Research And UK Defence Science & Technology Laboratory
4/26/2024
Touchlight, a biotechnology CDMO pioneering enzymatic DNA production has been awarded a second grant from the Office of Naval Research (ONR) and the Defence Science and Technology Laboratory (Dstl) to continue work with Professor Shelley Minteer’s research group, Missouri University of Science and Technology, to further propel the development of DNA-enabled biobatteries.
-
Applied DNA Awarded Contract By HDT Bio For Rapid Vaccine Development Program
4/25/2024
Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio (the “Project”).
-
FibroBiologics Plans To Collaborate With Charles River To Manufacture Fibroblast-Based Spheroids
4/25/2024
FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.
-
Regeneron And Mammoth Biosciences Collaborate To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases
4/25/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.
-
Merck Invests More Than € 300M In New Life Science Research Center In Germany
4/25/2024
Merck, a leading science and technology company, is investing more than € 300M in a new research center at its global headquarters in Darmstadt, Germany.